Breaking The Mold On Breast Cancer

An interview with noted Hadassah oncologist Dr. Tamar Peretz on genetic testing, mammograms and why the one-size-fits-all protocol no longer makes sense.

Deputy Managing Editor

Dr. Tamar Peretz is the director of Hadassah’s Sharett Institute of Oncology in Jerusalem and interim director general of the Hadassah Medical Organization in Jerusalem; at Hadassah, she leads the team whose genetic research and clinical studies have led to groundbreaking discoveries on BRCA1 gene mutations in the Ashkenazi community and new prevention, diagnosis and treatment approaches.

Dr. Tamar Peretz, left, with Fran Drescher at the Cancer Schmancer Women’s Health Summit in New York. Courtesy of Hadassah

Angelina’s `Jewish Gene’

The actress wrote a new NYT oped about her prophylactic surgery; here's the JW's take on all the talk.

Special To The Jewish Week

Celebrity Angelina Jolie's recent decision to opt for prophylactic surgery after she determined she is a carrier of a mutation in the BRCA1 gene has prompted media attention the world over. Media descriptions of her “Jewish gene”, however, are misguided. 

As Angelina Jolie has found, you don't have to be of Jewish descent to carry the BRCA1 or BRCA2 genes.
Syndicate content